Acquired Resistance to Therapy Network (ARTNet)

The Acquired Resistance to Therapy Network (ARTNet), of @theNCI focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at nciartnet.org and t.ly/ZbxF3

Don't wait-register now for the CAP-IT Virtual Annual Summit on July 24, 2025! Open to the public with exciting talks on cancer prevention and interception. 🔗 Register: tinyurl.run/M3wsBV ℹ️ Info: NCICAPIT.org 📧 [email protected] #CancerPrevention #NCICAPIT

Reactome is an open-source, peer-reviewed pathway database providing intuitive tools for visualizing and analyzing molecular pathways, advancing research, genomics, and systems biology since 2003. Co-led by Dr. Guanming Wu of the ARTNet U54 center at @OHSUNews. Explore:…

This new paper from CAP-IT U24 center @RoswellPark proposes a machine learning-assisted inferential procedure under Rosenbaum’s exact test framework—replacing linear models with flexible nonparametric ones. #CAPITPublication #ClinicalTrials #Biostats #MachineLearning #RCTs…

📢 New in Cancer Cell: Radiotherapy is essential for local control—but can it unintentionally accelerate growth of distant metastases? We examine how RT-induced EGFR signaling and immune modulation may fuel metastatic progression. 🧠🧬🔬 Read: doi.org/10.1016/j.ccel…

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study Adding chemo to osimertinib may benefit patients w/ EGFR + TP53 (L858R) more than those w/ Exon 19 del nature.com/articles/s4159…

Online now: Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer dlvr.it/TLdyFP

Nature research paper: Nerve-to-cancer transfer of mitochondria during cancer metastasis go.nature.com/3HYTQie

Are you an early stage researcher? Check out the newly released #FundingOpportunity for the #NIH Director’s New Innovator Award to fund exceptionally creative scientists proposing innovative, high-impact projects. Learn more: bit.ly/4jXnbXQ

Online Now: Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma dlvr.it/TLZk25

#ARTNetPublication

A new study funded by the NIH sheds light on how the 3D organization of #DNA inside the nucleus affects its vulnerability to #chemotherapy drugs like cisplatin – offering new insight into tackling #chemoresistance. Read the full story: go.nih.gov/sb7fF5A #CancerResearch

Online Now: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma dlvr.it/TLQ4ty

Online Now: A unified pan-cancer proteome atlas dlvr.it/TLPtvc

New study from the ARTNet BAATAAR-UP center in @JTOonline : Targeting WEE1 may overcome osimertinib resistance driven by ARID1A mutations in EGFR-mutant lung cancer. A promising strategy to tackle a major clinical hurdle in #NSCLC treatment. Congrats to @BivonaLabUCSF…

New in @NatureMaterials:Replacing PEG with poly(carboxybetaine) lipids in mRNA-LNPs boosts delivery efficiency, reduces immunogenicity, and prevents efficacy loss from repeat dosing: offering a safer, more effective platform for mRNA therapeutics. Kudos to Drs. @JiangShaoyi,…

New #JITC article: Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer bit.ly/4kSNTlB

NEW content online! Neuro-immune cross-talk in cancer bit.ly/3TuULJG

We’re excited to announce that the CAP-IT Virtual Annual Summit will be held on July 24, 2025! Register here: docs.google.com/forms/d/e/1FAI…… For more information please visit : NCICAPIT.org or email: [email protected] #CancerPrevention #NCICAPIT

🚨Roadmap 🚨 Alice Soragni @soragnilab, Erik S. Knudsen @RoswellPark & Co discuss the mechanisms of acquired resistance and the models to better study it to advance predictive and proactive prevention in cancer therapy. 📖 ⬇️ bit.ly/3Hv6qpj